Bio Rad Laboratories Inc expected to post earnings of $2.15 a share - Earnings Preview

Bio-Rad Laboratories

04/05/2024 03:03

* Bio Rad Laboratories Inc  BIO.N   BIO  is expected to show
a
fall in quarterly revenue when it reports  results on May 7 for
the period ending March 31 2024
    * The Hercules California-based  company is expected to
report a
8.5% decrease in revenue to $619.092 million from $676.84
million a year ago, according to the mean estimate from 5
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Bio Rad Laboratories Inc
is
for earnings of $2.15 per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Bio Rad
Laboratories Inc is $420.00​, above​ its last closing price
of $279.83. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Dec. 31 2023  2.81        2.82       3.10      Beat    10
 Jan. 1 2023   2.81        2.78       2.33      Missed  -16.3
 Jun. 30 2023  2.68        2.68       3.00      Beat    12​
 Mar. 31 2023  3.59        3.54       3.34      Missed  -5.7
 ​​Dec.        3.43        3.45       3.31      Missed  -4
 31 2022                                                
 Sep. 30 2022  2.83        2.78       2.60      Missed  -6.5​
 Jun. 30 2022  2.90        2.80       3.38      Beat    20.8
 Mar. 31 2022  3.45        3.40       4.94      Beat    45.2
 This summary was machine generated May 4 at 02:02 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)